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Abstract
Background. Left ventricular reverse remodeling (LVRR) determines clinical status and outcomes in dilated 
cardiomyopathy (DCM). The extent of myocardial fibrosis is connected to the systolic function of the heart. 
The recent discovery of the contribution of microRNAs (miRs) to the regulation of cardiac remodeling, LVRR 
and fibrosis warrants exploration.
Objectives. The aim of the study was to examine the predictive value of circulating and myocardial miR 
expression for LVRR in DCM.
Material and methods. Seventy consecutive DCM patients (age 48 ±12.1 years, 90% male, ejection 
fraction (EF) 24.4% ±7.4%) were included in the study. At baseline, all patients underwent clinical assess-
ment, echocardiography, venous blood sampling, and right ventricular endomyocardial biopsy. Circulating 
and myocardial miRs (miR-21, -26, -29, -30, -133a, and -423) were measured with quantitative real-time 
polymerase chain reaction (qRT-PCR). LVRR was defined as an increase in EF ≥ 10%, accompanied by a de-
crease in left ventricle end-diastolic diameter (LVEDd) ≥10% or LVEDd ≤ 33 mm/m2 between baseline and 
3-month follow-up.
Results. At the 3-month follow-up, 4 patients had died and 3 patients had incomplete data. The remaining 
patients were divided according to the presence of LVRR into LVRR-present (n = 32, 51%) and LVRR-absent 
(n = 31, 49%) groups. Out of all the circulating and tissue miRs under study, only myocardial expression 
of miR-133a significantly differed between the LVRR-present and LVRR-absent group (1.22 (0.47–1.90) vs 0.61 
(0.25–0.99) ΔCq, respectively, p < 0.01). miR-133a was found to be a significant LVRR predictor in unadjusted 
(odds ratio (OR) = 2.81 (1.23–6.40), p < 0.05) and adjusted for duration of disease, left ventricle end-diastolic 
(LVED) volume (LVEDvol), hs-troponin-T, and NT-proBNP (OR = 5.20 (1.13–24.050, p < 0.05) models.
Conclusions. From all of the circulating and tissue miRs, only myocardial miR-133a showed increased 
expression in LVRR-present patients and was found an independent LVRR predictor. This indicates a link 
between miR-133 and cardiac remodeling in DCM.
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Introduction
Heart failure (HF) is a worldwide problem with a preva-
lence of 1–2% in the general population.1 In a younger pop-
ulation, between 20 and 40 years of age, the most common 
HF etiology is dilated cardiomyopathy (DCM).2 It is a pro-
gressive myocardial disease, characterized by ventricular 
wall thinning and dilation accompanied by gradual func-
tional impairment.3 During the progression of the dis-
ease, the left ventricle (LV) undergoes profound adverse 
morphological and functional changes, termed remodel-
ing. This process has a crucial role in the transition from 
the compensated and oligo-symptomatic DCM phenotype 
to overt and symptomatic HF. Cardiac fibrosis contributes 
to adverse remodeling.4
Following optimal medical therapy, in approx. 30–50% 
of DCM patients, the heart – and the LV in particular – can 
undergo LV reverse remodeling (LVRR). This is a broad 
term that describes beneficial changes in LV morphol-
ogy (decrease of  LV size) and function (improvement 
of LV systolic function).5,6 The current recommendations 
of the European Society of Cardiology (ESC) on HF man-
agement take the possibility of the occurrence of LVRR 
into account and emphasize the need for regular moni-
toring of cardiac morphology and function.1 Since LVRR 
is one of the strongest prognostic predictors in HF and 
DCM, many investigations have been carried out to deter-
mine LVRR predictors.5 Despite huge efforts being made 
towards LVRR prediction as well as the treatment of HF 
through LVRR induction, HF is still one of the most com-
mon causes of mortality worldwide.
The recent discovery of the contribution of micro RNAs 
(miRs) to the regulation of cardiac remodeling and fibrosis 
suggests their potential diagnostic and therapeutic role. 
In mice, up- and downregulation of specific miRs were 
found to be related to various aspects of cardiac  pathology.7,8 
From previous studies, miR-21, miR-26, miR-29, miR-30, 
miR-33a, and miR-133a are known to be related to myo-
cardial fibrosis, cardiac remodeling and cardiac hypertro-
phy.9,10 These miRs are believed to be valuable biomarkers 




Seventy consecutive DCM patients with a clinical and 
echocardiographic diagnosis of DCM (63 men and 7 women, 
with an average age of 48 ±12.1 years), admitted to the car-
diology clinic between July 2014 and October 2015, were 
included in the study. All patients were willing to participate 
in the study. During the study, 4 patients died and 3 patients 
had incomplete data before the 3rd month of follow-up. For 
the purposes of this study, we analyzed 63 of the 70 patients 
(84%) with available laboratory and echocardiographic data 
at baseline evaluation and after 3 months.
Dilated cardiomyopathy was diagnosed by the presence 
of LV dilation (>117% of predicted LV end diastolic diameter 
(LVEDd)) and impaired LV systolic function (ejection frac-
tion (EF) <35%) shown on detailed echocardiogram, after 
the exclusion of significant coronary artery disease, arterial 
hypertension, congenital heart disease, and primary heart 
valve disease – in line with the current ESC 2017 recommen-
dations.3 Moreover, patients were excluded from the study 
based on the presence of chronic liver insufficiency, neo-
plasms, peripheral atherosclerosis, as well as bone and joint 
diseases affecting collagen metabolism and circulating levels 
of procollagens. All patients had optimal HF therapy with 
regards to drug type and dosage, and stable HF symptoms 
(according to the New York Heart Association (NYHA) 
scale) for at least 2 weeks before inclusion in the study.
This study was approved by the Jagiellonian Univer-
sity Ethics Committee (protocol No. KBET/164/B/2014, 
date of approval: June 30, 2014). Written informed con-
sent was obtained from all participants prior to inclusion 
in the study. All procedures performed were in accordance 
with the ethical standards of the institutional research 
committee and the 1964 Helsinki declaration and its later 
amendments, or comparable ethical standards.
Study design
All patients underwent detailed clinical assessment, 
laboratory tests, echocardiography, electrocardiography, 
cardiopulmonary exercise, and right ventricular endomyo-
cardial biopsy at the baseline of the study. All subjects were 
also evaluated at the 3rd month of follow-up and underwent 
clinical and echocardiography examination.
Right ventricular biopsy
Endomyocardial biopsy procedures were performed by 
experienced operators via a femoral or jugular vein ap-
proach. Long, flexible biopsy forceps (7 French size) with 
small jaws (Cordis®; Johnson & Johnson Co, Miami Lakes, 
USA) were used. Up to 5 myocardial samples were obtained 
from the RV septum and then stored in formalin for light 
microscopic examinations of fibrosis (2–3 samples) or fro-
zen in OCT-embedding medium and then stored at −80°C 
for further studies (2 samples; Fig. 1).
Laboratory measurements
At baseline, venous blood samples were drawn in a fasted 
state in the morning after 30 min of supine rest. All ve-
nous blood samples, after centrifuge, were stored at −20°C 
until assay. Before examination, small tissue samples from 
the right ventricular biopsy from the baseline were ho-
mogenized. Levels of circulating and tissue miRs were 
established with quantitative polymerase chain reaction 
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(qPCR).11 With a MirVana kit (Life Technologies, Carlsbad, 
USA) and according to the manufacturer’s protocol, RNA 
was extracted from 100 μL of sample. Then, with a Taq-
Man Advanced MicroRNA cDNA Synthesis Kit (Life Tech-
nologies), reverse transcription was performed on 2 μL 
of extracted RNA. After ×10 dilution of the cDNA samples, 
the qPCR reaction was conducted with TaqMan Advanced 
MasterMix and TaqMan Advanced Assays on 384-well 
plates. The qPCR targeted hsa-miR-21-5p, hsa-miR-26a-5p, 
hsa-miR-29b-3p, hsa-miR-30a-3p, hsa-miR-30c-5p, and 
hsa-miR-133a-3p. Fifteen-microliter reactions were pre-
pared with the Bravo pipetting station (Agilent Technolo-
gies, Santa Clara, USA) and the real-time qPCR reaction 
(RT-qPCR) was run and read on the CFX384 Real Time 
PCR Detection System (Bio-Rad Laboratories, Hercules, 
USA). We tested miR-423, selected on the basis of our 
previous experience with qPCR in plasma samples. Mean 
quantitation cycle (Cq) values were normalized to the geo-
metric mean of hsa-miR-423, which was selected as a rela-
tively stable control in pilot experiments. Data was ex-
pressed for each sample as ΔCq, which is the difference 
between the Cq value, the miRNA of interest and the geo-
metric mean of miR-423 for a particular sample.
Echocardiography
All echocardiographic examinations were performed 
in accordance with the recent European and American 
recommendations.12 Volumetric and EF measurements 
were performed in apical 4- and 2-chamber views, utilizing 
the method of disk summation – modified Simpson’s rule. All 
echocardiographic parameters were calculated as the mean 
of 3 measurements for patients with sinus rhythm, and 
of  5  measurements for patients with atrial fibrillation. 
Chamber diameters, areas and volumes were normalized 
for body surface area (BSA). All  examinations were made 
on commercially available equipment (Vivid 7 GE Medical 
System, Horten, Norway) with a phased-array of 1.5–4 MHz 
transducer by experienced echocardiographers.
Definition of LVRR
Left ventricle reverse remodeling was defined as an abso-
lute increase in EF of minimum 10%, with a simultaneous 
decrease in LVEDd of at least 10% or an indexed LVEDd 
under 33 mm/m2.5 Left ventricular reverse remodeling was 
calculated between the baseline and 3rd month of follow-up 
measurements (Fig. 2).
Statistical analysis
Tissue and circulating levels of miRs are presented as me-
dian and quartiles, and other parameters as mean ± stan-
dard deviation (SD). All variables were tested for normal 
distribution of the data with the Shapiro–Wilk test. Com-
parisons of clinical and echocardiographic parameters 
between the LVRR-present and LVRR-absent groups were 
conducted with t-tests when normality was confirmed, 
or with a Mann–Whitney test for parameters without 
a  normal distribution. The  impact of  circulating and 
Fig. 1. Right ventricular bioptates. Biopsy specimens stained with collagen specific Masson’s trichrome. Panel A – massive diffuse (interstitial) fibrosis 
(arrowheads). Compression of the adjacent myocytes (arrows). Panel B – widespread endocardial fibrosis (arrowheads)
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myocardial tissue miRs on the probability of LVRR was 
analyzed with uni- and multivariate logistic regression 
methods. Areas under the receiver operating characteris-
tics (ROC) curves (areas under the curve (AUC)) were used 
to establish the most optimal cut-off values of the analyzed 
parameters and their diagnostic accuracy. For regression 
analysis, log10 of the NT-proBNP level was used. All re-
sults were considered statistically significant when p-value 
was <0.05. The STATISTICA package v. 13.0 (StatSoft, Inc., 
Tulsa, USA) was used for the statistical analysis.
Results
Baseline characteristics
Sixty-three patients with complete data were divided ac-
cording to the presence of LVRR: an LVRR-present group 
(n = 32, 51%) and an LVRR-absent group (n = 31, 49%). 
Compared with the LVRR-absent individuals, LVRR-pres-
ent patients were characterized by a shorter duration of HF 
symptoms (p < 0.01), a smaller LV dimension (LVEDd, 
p < 0.001) and volume (LVEDvol, p < 0.001), as well as low-
er serum levels of troponin (p < 0.05) and NT-proBNP 
(p < 0.01) (Table 1).
Comparison of miRNA plasma  
and tissue levels
Expression of all circulating miRs were similar in both 
groups. However, myocardial expression of miR-133 was 
significantly higher in  patients with LVRR (p  <  0.01) 
(Table 2).
The predictive value of clinical, 
echocardiographic and laboratory 
parameters for LVRR
All parameters, including symptom duration time, 
LVEDvol, troponin, NT-proBNP and myocardial miR-133a, 
that differentiated LVRR-present and LVRR-absent were 
found to be LVRR predictors in ROC analyses and univariate 
regression. The respective results are presented in the Ta-
ble 3 and Fig. 3A–E. Finally, only LVEDvol and miR-133 
were found to be significant predictors in multivariate 
analysis, adjusted for symptom duration time, and tropo-
nin (hs-TnT) and NT-proBNP levels (Table 4). The com-
bined model was found to be superior compared to models 
with only a single variable (AUC = 0.93, 95% CI = 0.85–1.00; 
specificity 85% and sensitivity 87.5%) (Fig. 3F).
Fig. 2. Apical four-chamber 
echocardiographic projections. 
Panel A and B – patient 
with LVRR (A – at baseline 
echo, showing grossly 
enlarged, thin-walled LV 
with severely impaired LV 
systolic function, EF – 22%; 
B – substantial decrease 
of LV cavity size alongside 
improvement of LV systolic 
function, EF – 42%). Panel 
C and D – patient without LVRR 
(C – baseline echo; D – lack 
of improvement of LV size and 
systolic function)
LV – left ventricle; LA – left 
atrium; RV – right ventricle; 
RA – right atrium; LVRR – left 
ventricular reverse remodeling.
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Table 1. Baseline characteristics of the study population, divided into groups with and without LVRR
Parameter LVRR-present group(n = 32, 51%)
LVRR-absent group
(n = 31, 49%) p-value
Age [years] 48.9 ±9.9 46.9 ±9.9 0.53
Sex [male] 29 (90.6%) 28 (90.3%) 0.97
BMI [kg/m2] 28.3 ±4.8 25.9 ±5.5 0.07
NYHA class 2.56 ±0.84 2.48 ±0.57 0.74
HF symptoms’ duration [ms] 14.7 ±29.9 35.8 ±40.8 0.005
QRS [ms] 102.8 ±30.0 114.5 ±36.0 0.24
LVEDd/BSA [mm/m2] 31.7 ±4.1 39.5 ±6.6 0.02
LVEDvol/BSA [mL/m2] 101.5 ±36.3 151.6 ±72.0 0.02
EF [%] 25.8 ±7.6 22.3 ±6.7 0.07
LAA [mm] 31.1 ±8.3 30.4 ±9.2 0.77
PA mean [mm Hg] 21.0 ±9.3 24.2 ±12.2 0.33
VO2peak [mL/kg/min] 15.7 ±4.5 16.4 ±7.0 0.78
Hb [g/dL] (14.0–18.0) 14.8 ±1.6 14.3 ±1.4 0.21
CK-MB [U/L] (UNL < 24) 12.9 ±4.9 13.5 ±5.5 0.52
hs-TnT [ng/mL] (UNL < 0.014) 0.016 ±0.01 0.028 ±0.02 0.02
hs-CRP [mg/dL] (UNL < 3.0) 11.9 ±29.2 7.7 ±18.9 0.07
NT-proBNP [pg/mL] (UNL < 125) 2,606 ±5,041 4,242 ±6,268 0.009
TGF-β [pg/mL] (4,639–1,4757) 2,867 ±1,472 2,358 ±975 0.22
CTGF [ng/mL] (2.3–42.5) 5.63 ±4.56 4.68 ±2.96 0.55
Galectin-3 [ng/mL] (8.6–10.9) 13.8 ±4.49 14.4 ±4.20 0.55
CRT 5 (15.6%) 15 (48%) 0.005
β-blocker 31 (96.9%) 31 (100%) 0.32
ACE-I 31 (96.9%) 29 (93.5%) 0.54
MRA 31 (96.9%) 28 (93.1%) 0.29
Furosemide 19 (59.4%) 19 (61.3%) 0.88
Data is presented as mean ±SD or n (%). BMI – body mass index; NYHA – New York Heart Association class; LVEDd/BSA – indexed LV end-diastolic diameter; 
LVEDvol/BSA – indexed LV end-diastolic volume; EF – ejection fraction; LAA – left atrium area; PA mean – mean pulmonary artery pressure; VO2peak – peak 
oxygen uptake; Hb – hemoglobin, CK-MB – myocardial fraction of creatine kinase; hs-TnT – high sensitivity troponin T; hs-CRP – high sensitivity C-reactive 
protein; NT-proBNP – amino-terminal pro B-type natriuretic peptide; TGF-β – transforming growth factor β; CTGF – connective tissue growth factor; 
CRT – cardiac resynchronization therapy; ACE-I – angiotensin converting enzyme inhibitor; MRA – mineralocorticoid receptor antagonist; UNL – upper 
normal limit.
Table 2. Comparison of plasma and cardiac tissue levels of selected microRNAs in patients with and without LVRR
microRNA LVRR-present group (n = 32) LVRR-absent group (n = 31) p-value
miR-21 [ΔCq] 0.19 (−0.12–0.50) 0.02 (−0.41–0.77) 0.77
miR-26 [ΔCq] −0.25 (−0.62–0.14) 0.33 (−0.64–0.94) 0.12
miR-29 [ΔCq] 2.87 (2.49–3.18) 2.72 (2.40–3.08) 0.81
miR-30a3 [ΔCq] 7.98 (6.73–8.78) 7.77 (6.82–9.43) 0.86
miR-30c5 [ΔCq] 4.31 (3.86–4.81) 4.03 (3.73–4.82) 0.65
miR-133a [ΔCq] 6.99 (6.31–8.94) 7.60 (5.73–9.07) 0.59
miR-423 [ΔCq] −0.25 (−0.62–0.14) 0.33 (−0.64–0.94) 0.12
Tissue miR-21 [ΔCq] 1.33 (0.73–1.92) 1.01 (0.40–1.47) 0.09
Tissue miR-26 [ΔCq] −1.33 (−1.77–−0.92) −1.41 (−1.72–−0.97) 0.54
Tissue miR-29a [ΔCq] 1.49 (0.87–1.91) 1.16 (0.64–1.51) 0.17
Tissue miR-29b [ΔCq] 1.38 (0.72–2.07) 1.07 (0.65–1.63) 0.21
Tissue miR-30c [ΔCq] −0.51 (−1.01–0.19) −0.73 (−1.03–−0.18) 0.26
Tissue miR-133a [ΔCq] 1.22 (0.47–1.90) 0.61 (0.25–0.99) 0.006
Data is presented as median and 95% confidence interval (95% CI).
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Discussion
Study findings
The main findings of  the  study can be summarized 
as follows: firstly, LVRR was present in half of DCM pa-
tients. Secondly, of  all the  circulating and myocardial 
miRs under study, myocardial miR-133a alone differen-
tiated LVRR-present and LVRR-absent groups. Thirdly, 
Fig. 3. ROC curves for LVRR prediction based on: HF symptom duration (A), LVED volume (B), troponin (C), NT-proBNP (D), and miR-133a levels (E), and ROC 
curve based on a model comprised of all parameters (F)
ROC – receiver operating characteristics; LVRR – left ventricular reverse remodeling; HF – heart failure.
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Table 3. Odds ratios (OR) and ROC analysis for LVRR prediction from univariate logistic regression analysis
Parameter
Univariate logistic regression ROC analysis Cut-off value 
(specificity, sensitivity)OR (95% CI) p-value AUC (95% CI) p-value
Duration of disease [months] 0.98 (0.97–0.99) 0.049 0.70 (0.57–0.83) 0.002 3 (68%, 63%)
LVEDvol [mL/m2] 0.993 (0.987–0.999) 0.02 0.68 (0.55–0.82) 0.009 187 (84%, 50%)
hs-TnT [ng/mL] <0.0001 (0–0.022) 0.03 0.69 (0.55–0.83) 0.007 0.011 (79%, 50%)
NT-proBNP [pg/mL] 0.29 (0.11–0.78) 0.02 0.70 (0.56–0.83) 0.005 826 (90%, 48%)
miR-133a [ΔCq] 2.81 (1.23–6.40) 0.015 0.71 (0.56–0.85) 0.003 1.016 (77%, 63%)
Duration of disease, LVED volume (LVEDvol), troponin (hs-TnT), NT-proBNP and myocardial miR-133a levels as LVRR predictors in univariate logistic regression
Table 4. The predictive value of duration of disease, LVEDvol, hs-TnT, 
NT-proBNP, and myocardial miR-133a for LVRR prediction – multivariate 
logistic regression analysis
Parameters OR (95% CI) p-value
Duration of disease 0.97 (0.94–1.01) 0.09
LVEDvol 0.99 (0.98–1.00) 0.03
hs-TnT <0.0001 (1*10−7–4*1012) 0.22
NT-proBNP 0.25 (0.03–1.98) 0.19
miR-133a 5.20 (1.13–24.05) 0.03
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myocardial miR-133a was found to be a significant LVRR 
predictor. The multivariate regression model, including 
HF symptom duration, myocardial mir-133a, LVEDvol, 
troponin and NT-proBNP levels were found to be highly 
accurate for LVRR prediction in DCM.
Predictors of left ventricle reverse 
remodeling in DCM
Left ventricular reverse remodeling is of paramount 
importance in DCM. The rate of LVRR differs between 
studies and depends on many factors, such as the defini-
tion of LVRR, time of assessment, management strategy, 
etc. In our cohort, LVRR was present in half of the patients, 
which is in line with the literature.5,13 The division of DCM 
patients by the presence of reverse remodeling is dictated 
by its significance in prognosis and strong correlation with 
survival in DCM.5,14 Improvement in myocardial function 
can occur spontaneously and in response to HF therapy 
(drugs, cardiac devices).15,16 In our group, nearly 100% 
of patients were receiving adequate therapy as  recom-
mended by the ESC (95% were on β-blockers, ACE-I and 
MRAs, and nearly 1/3 had received cardiac resynchroniza-
tion therapy (CRT)).1,13
The topic of LVRR has been intensively investigated and 
several LVRR independent predictors have been identi-
fied such as: longer symptom duration and higher NYHA 
class, larger LVEDd and LVEDvol and left atrium (LA) size, 
higher troponin and NT-proBNP levels, late gadolinium 
enhancement in magnetic resonance, left bundle branch 
block and longer QRS duration, and higher grade of mi-
tral regurgitation.5,15,17 In our analysis, symptom duration, 
LVED volume, and troponin and NT-proBNP levels were 
significant LVRR predictors in DCM patients.
Circulating and cardiac tissue miRs 
in cardiac remodeling and reverse 
remodeling
Certain miRs under study, including miR-21, -26, -29, 
-30, -33a, -133a, and -423, are known to be related to myo-
cardial fibrosis, which leads to  cardiac remodeling.9,18 
Previously, we reported associations between circulat-
ing miR-26 and miR-30, and collagen volume fraction, 
which is a quantitative expression of myocardial fibrosis 
in DCM.10 However, in this study, we found no connection 
between miR-26 or -30 and reverse remodeling.
Little is known about the role of miRs in cardiac re-
verse remodeling and LVRR, especially in DCM. Recent-
ly, it was shown that circulating miR-208a and miR-29a, 
which regulate hypertrophy, fibrosis and inflammation, 
were associated with LVRR.19,20 Furthermore, circulat-
ing miR-16, miR-27a, miR-101, and miR-150 were related 
to cardiac function improvement after myocardial infarc-
tion. In another study, higher expression of circulating 
miR-208, -208b and -499 were found in DCM patients when 
compared with healthy controls.21–23 Both Sucharov et al. 
and Shah et al. have recently reported dynamic changes 
in miRNA expression during LVRR, including an increase 
in miR-21, especially in response to β-blockers.24,25 How-
ever, we did not confirm any differences in miR-21 levels 
between DCM patients with and without LVRR. Moreover, 
Szczerba et al. found a significant decrease of miRs during 
pregnancy as protection from myocardial fibrosis during 
volume overload in pregnancy.26
Out of all the circulating and myocardial miRs under 
study here, we report for the first time the association 
between myocardial miR-133a and LVRR. Of note, none 
of the other circulating and tissue miRs, including circulat-
ing miR-133a, were related to LVRR. Based on previous lab-
oratory studies, miR-133a has proven to have an important 
role in heart physiology and pathology, including cardiac 
development, hypertrophy, remodeling, and fibrosis.27–30 
In a murine HF model, miR-133a was found to play an im-
portant role in the hypertrophic pathway. Interestingly, 
decreased levels of miR-133a cardiac tissue expression were 
linked with adverse cardiac remodeling, whereas increased 
miR-133a expression was related to a reduction of cardiac 
fibrosis and favorable ECM remodeling.31–33 Moreover, 
miR-133a was found to protect myocardial tissue and de-
crease apoptosis of cardiomyocytes after myocardial in-
farction.34 On the other hand, in recent studies, we did not 
observe any relations between either circulating or myo-
cardial miR-133a with fibrosis, expressed either qualita-
tively or quantitatively.6 This is in line with the findings 
from other authors, who reported a lack of straightforward 
relations between particular miRs, including miR-133a, 
and cardiac fibrosis.33,35
Furthermore, several authors have reported close links 
between miR-133a and outcomes in various cardiac con-
ditions. Circulating miR-133a was found to be a marker 
in the prediction of all-cause mortality and major adverse 
cardiovascular events in patients with coronary artery 
disease.22,36–39 Moreover, Besler et al. showed a connec-
tion between myocardial miR-133 levels and clinical out-
comes in inflammatory cardiomyopathy.32 Widera et al. 
and Keller et al. showed an improvement in risk stratifica-
tion with a panel consisting of circulating miRs, including 
miR-133, outperforming troponin level.37,40 In line with 
this, we have recently reported that myocardial miR-133a 
was an independent predictor of survival in DCM.6 Bear-
ing this in mind, the present observation that myocardial 
miR-133a is independently associated with LVRR further 
reinforces the aforementioned findings that indicate that 
LVRR is one of the strongest factors influencing outcomes.
Study limitations
There are several study limitations which we would like 
to comment on. The study population is relatively small, 
but, on the other hand, the utilization of biopsy and tissue 
qRT-PCR to study miRs makes our study one of the largest 
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in the field. Another limitation is the utilization of qPCR, 
which allows one to measure only selected miRs, whereas 
next generation sequencing enables identification of vir-
tually all mRs. Thus, we concentrated on only a few miRs 
which were previously linked with fibrosis, and by doing 
so excluded hundreds of other miRs that may also have 
a role in fibrosis and LVRR.
Conclusions
Among circulating and tissue miRs: miR-21, -26, -29, 
-30, -133a, and -423, only myocardial miR-133a expression 
was increased in patients with LVRR. Moreover, myocar-
dial miR-133a was found to be an independent predictor 
of LVRR, and has been previously reported as a mortality 
predictor in DCM. This may indicate that miR-133a has 
a potential role in the reverse remodeling process in DCM 
and its potential role in anticipating LVRR in DCM. This 
might be further exploited by miR-133a expression level 
restoration with miRNA mimics.
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